In her new role, Dr. Horton will support the company in its phase 3 clinical trial of its crofelemer drug meant to prevent diarrhea in cancer patients receiving cancer therapy.
Dr. Horton received her medical degree from the University of Florida in Gainesville and completed a residency and fellowship at the University of California San Francisco. She has previous leadership experience at various healthcare companies, including being the CMO of Coherus BioSciences, Itero Biopharmaceuticals and SMC Biotechnology.
Napo Pharmaceuticals is a subsidiary of Jaguar Health, based in San Francisco.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
